Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.

BACKGROUND Although systems to collect information about suspected adverse drug reactions (ADRs) were established in many countries and by the WHO in the 1960s, few studies have examined reported ADRs related to national income. OBJECTIVE The aim of the study was to characterize ADRs reported to the WHO-ADR database, VigiBase™, and to relate data to national income. METHODS We analysed ADR reports submitted to VigiBase™ from 2000 to 2009 with respect to reporting rate, age and sex of patient, type, seriousness and medications. Reports were also analysed with respect to national income level, classified in accordance with the World Bank definition: low, lower-middle, upper-middle and high. RESULTS We analysed 1,359,067 ADR reports including 3,013,074 ADRs. Overall, 16% of reports were serious and 60% were reported for females. High-income countries had the highest ADR reporting rates (range 3-613 reports/million inhabitants/year) and low-income countries the lowest (range 0-21). Distribution of ADRs across income groups with respect to age group, seriousness and sex was non-significant. Overall, the majority of ADRs were reported for nervous system medications, followed by cardiovascular medicines. Low-income countries reported relatively more ADRs for antiinfectives for systemic use than high-income countries, and high-income countries reported more ADRs for antineoplastic and immunomodulating agents than lower-income groups. CONCLUSION This study showed that high-income countries had the highest ADR reporting rates and low-income countries the lowest, with large variations across countries in each group. Significant differences in ADR reporting rates were only found for ADRs of the type 'skin and subcutaneous tissue disorders' and for the therapeutic groups 'antiinfectives for systemic use' and 'antineoplastic and immunomodulation agents'. To strengthen ADR reporting rates, especially in low-income countries, more research is needed about the impact of organizational structures and economic resources of national pharmacovigilance centres and ADR reporting practices on the large variations in ADR reporting rates within income groups.

[1]  J. Cope,et al.  Pediatric drug surveillance and the food and drug administration's adverse event reporting system: an overview of reports, 2003–2007 , 2009, Pharmacoepidemiology and drug safety.

[2]  A. Mwango,et al.  Pharmacovigilance and new essential drugs in Africa: Zambia draws lessons from its own experiences and beyond , 2007, Global public health.

[3]  D. Durrheim,et al.  Malaria Pharmacovigilance in Africa , 2007, Drug safety.

[4]  S. Olsson,et al.  Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring , 2011, Malaria Journal.

[5]  D. Capellà,et al.  Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs , 2004, European Journal of Clinical Pharmacology.

[6]  A. Blenkinsopp,et al.  Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. , 2007, British journal of clinical pharmacology.

[7]  K. Barnes,et al.  Establishing pharmacovigilance programs in resource-limited settings: the example of treating malaria , 2010, Expert review of clinical pharmacology.

[8]  N. Suttorp,et al.  Intravenous Artesunate for Severe Malaria in Travelers, Europe , 2011, Emerging infectious diseases.

[9]  Ebba Holme Hansen,et al.  Consumer Reporting of Adverse Drug Reactions , 2009, Drug safety.

[10]  Bruce M Psaty,et al.  Detection, verification, and quantification of adverse drug reactions , 2004, BMJ : British Medical Journal.

[11]  G. Dukes.  The Effects of Drug Regulation , 1985, Springer Netherlands.

[12]  E. Hansen.  Technology Assessment in a User Perspective-Experiences with Drug Technology , 1992, International Journal of Technology Assessment in Health Care.

[13]  Munir Pirmohamed,et al.  Pharmacovigilance in developing countries , 2007, BMJ : British Medical Journal.

[14]  N. Ford,et al.  Substandard medicines in resource‐poor settings: a problem that can no longer be ignored , 2008, Tropical medicine & international health : TM & IH.

[15]  Andy Stergachis,et al.  Pharmacovigilance Activities in 55 Low- and Middle-Income Countries , 2010, Drug safety.

[16]  K. Barnes,et al.  Spontaneous Adverse Drug Reaction Reporting in Rural Districts of Mozambique , 2008, Drug safety.

[17]  S. Olsson,et al.  The Role of the WHO Programme on International Drug Monitoring in Coordinating Worldwide Drug Safety Efforts , 1998, Drug safety.

[18]  K. Stowman.  World health statistics. , 1949, The Milbank Memorial Fund quarterly.

[19]  G. Faich.  US Adverse Drug Reaction Surveillance 1989–1994 , 1996, Pharmacoepidemiology and drug safety.